Tissue inhibitor of metalloproteinases-1 (TIMP-1) regulates matrix metalloproteinase activity, acts as a growth stimulator and inhibits apoptosis. We developed transgenic mice to evaluate the relevance of circulating versus mammary TIMP-1 in mammary carcinogenesis. The transgene was placed under the control of the albumin (Alb) promoter for the production of large amounts of TIMP-1 in the liver and release into the systemic circulation to achieve chronically elevated blood levels. The initial 7,12-dimethylbenz[a]anthracene (DMBA) mammary carcinogenesis study showed greatly decreased tumor incidence in heterozygous Alb-TIMP-1 mice (25%), compared with their wild-type (wt) littermates (83.3%). Metastatic mammary carcinomas were induced in the Alb-TIMP-1 mice through breeding with mice expressing the polyomavirus Middle T antigen (MT) under the control of the mouse mammary tumor virus-long terminal repeat (MMTV-LTR). Both the mammary tumor burden and the incidence of lung metastases were lower in the Alb-TIMP-1/MMTV-MT mice than their MMTV-MT littermates. Analysis of the Alb-TIMP-1/MMTV-MT tumors showed evidence of decreased proliferative activity and inhibition of apoptosis, whereas microvascular density was not affected. Transgenic expression of TIMP-1 in mammary epithelial cells was accomplished by using MMTV-LTR. In contrast to the Alb-TIMP-1 mice, there was insignificant difference in the growth of both DMBA-and MT-induced mammary tumors between heterozygous MMTV-TIMP-1 mice and their wt littermates. The MT-induced mammary tumors of the MMTV-TIMP-1 mice were separated intò low' and`high' TIMP-1 expressing groups. The`high' TIMP-1 expressing tumors exhibited significantly higher proliferative activity than the tumors of the MMTV-MT only mice, whereas the number of apoptotic cells and microvascular density were not different. The findings of this study show that circulating TIMP-1, but not mammary-derived TIMP-1, has growth suppressive effects on DMBA and MT-induced mammary carcinomas.
Introduction
Under physiological conditions, extracellular matrix (ECM) turnover is tightly regulated by coordinated expression of proteolytic enzymes, including matrix metalloproteinases (MMPs) and their endogenous inhibitors, TIMPs (1, 2) . The MMP/TIMP-1 balance is often lost in malignant tumors, resulting in increased degradation of ECM, including basement membrane (3, 4) . Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a secreted glycoprotein, which is present in body fluids and the ECM (5) . When the TIMP-1 sequence was first determined in 1986 (6), it was found to be identical to that of erythroid potentiating activity, a growth factor for erythroid precursor cells (7) . TIMP-1 is also a mitogen for various other cell types (8EE11). Additionally, TIMP-1 has been established as an inhibitor of angiogenesis (12EE14) and a survival factor (15EE21). Translocation of TIMP-1 to the nucleus may reflect events involved in its growth promoting or anti-apoptotic functions (22) . TIMP-1 has paradoxical effects on tumor progression in experimental models. Recombinant TIMP-1 (rTIMP-1) inhibits experimental metastasis of murine melanoma cells (23) and ras-transfected embryonic stem cells (24) . Over-expression of TIMP-1 is associated with decreased tumorigenicity and metastatic capability of different tumor cell types (25EE27) and down-regulation of TIMP-1 confers oncogenicity and increased invasiveness on Swiss/3T3 cells and embryonic stem cells (28, 29) . Conversely, overexpression of TIMP-1 in rat mammary carcinoma cells results in up-regulation of vascular endothelial growth factor (VEGF) and increased growth in nude mice (30) . Also, TIMP-1 expression in tumorigenic cells can either increase or suppress lung metastases (31) and TIMP-1 expression is increased in various types of human malignancies, including breast cancer (32EE35). High TIMP-1 levels are associated with poor prognosis in lymphoma (36) and carcinomas of breast (37EE41), lung (42) , stomach (43) , colon (44) , bladder (45) and prostate (46) . In invasive breast cancer, the TIMP-1 signal is present in both tumor and stromal cells with the most intense signals at the tumorEEstromal interface (35) .
A number of synthetic MMP inhibitors have been developed, which showed antitumor activity in murine models (47EE49). Regrettably, these inhibitors failed to show therapeutic benefits in clinical cancer trials (50) . We have established transgenic mice to further evaluate the effects of chronically
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Materials and methods

Generation of transgenic mice
Full-length human TIMP-1 cDNA (624 bp, 63 to 687) was isolated from the HT-1080 fibrosarcoma cell line and cloned into the EcoRI and NotI sites of the cytomegalovirus (CMV) promoter driven pCI-neo vector (Promega, Madison, WI) as described previously (30) .
The CMV promoter was then deleted from the vector by digestion with BglII and I-PopI and replaced with the mouse albumin (Alb) promoter containing the enhancer and proximal promoter regions (51) to produce the Alb-TIMP-1 vector. The mouse mammary tumor virus (MMTV)-TIMP-1 vector was made by deleting the CMV promoter from the pCI-neo vector with EcoRI and SmaI. It was replaced with MMTV-long terminal repeat (LTR) obtained from the pMAMneo vector (Clontech, Palo Alto, CA). Verification of the transgene constructs was done by restriction mapping and nucleotide sequencing. Linearized Alb-TIMP-1 (3.7 kb Hga fragment) or MMTV-TIMP-1 (3.7 kb BspHI, DRAIII fragment) were injected into fertilized eggs from C57BL/6 J-CBA (B6CBA) hybrid mice. Founders were identified by Southern blot analysis of digested genomic tail DNA. The DNA was separated in 0.8% agarose gel, transferred to nylon membranes, and hybridized with 32 P-labeled TIMP-1 cDNA probe, consisting of a 930 bp fragment digested with EcoRI and PvuI. Heterozygous Alb-TIMP-1 and MMTV-TIMP-1 lines were developed from the founders with the highest TIMP-1 mRNA expression in liver and mammary glands, determined by northern blot analysis.
Transgenic offspring were identified using PCR analysis of genomic tail DNA. The PCR conditions were: 30 cycles at 94 C for 1 min, 50 C for 2 min and 72 C for 3 min. The primers for both Alb-TIMP-1 and MMTV-TIMP-1 were: GAGTACTTAATACGACTCACTATAGG (sense) and GCGGCCG-CGATTCAGGCTATCTGGGA (antisense). The mice were maintained and then killed according to NIH guidelines for animal care. Tissues were either snap-frozen or fixed in 10% buffered formalin and embedded in paraffin. The blood was collected in plasma-separation tubes (PST, Becton-Dickerson, Franklin, NJ), held on ice for 30 min, and then centrifuged at 3000 g for 25 min. The plasma samples were collected and stored at À20 C until used. At the end of the study, the mice were killed and necropsied. The major organs were subjected to macroand microscopic examination. A second DMBA study was undertaken in 16 heterozygous MMTV-TIMP-1 and 14 wt littermates. These mice received a single dose of MPA (100 mg) in a slow release pellet at 6 weeks of age. The same DMBA dosing regimen was used as in the Alb-TIMP-1 mice. The mice were killed 10 weeks after the last DMBA dose. All of the mammary tumors were excised and weighed. For induction of metastatic mammary carcinomas, heterozygous Alb-TIMP-1 and MMTV-TIMP-1 females were crossed with MMTV-Middle T antigen (MT) males (52) , which were kindly provided by Dr William J.Muller (McMaster University). Genotyping for MT was performed by PCR of genomic tail DNA. The PCR primers and conditions for the MT construct have been described elsewhere (52, 53) . All animals were killed at 18 weeks of age and necropsied. All mammary tumors were excised and weighed. MannEEWhitney U-test was used to calculate the median values of tumor weights of the DMBA-and the MT-induced mammary carcinomas in the Alb-TIMP-1 and MMTV-TIMP-1 mice.
Mammary carcinogenesis studies
The two largest tumors from each mouse were cut into pieces and either snap frozen and stored at À80 C, or fixed in 10% buffered formalin for H&E or special staining. The lungs were inflated with 10% buffered formalin. Four H&E stained cross sections of the lungs, cut 50 mm apart, were used to enumerate micro-and macrometastases. The average surface area of individual metastases was also determined, using images taken at 7.5Â magnification, and stored by Nikon ACT-1 software. The metastases were captured with Adobe Photoshop software, counted, and measured, using NIH Image 1.62f software.
Northern blot, RTEEPCR and angiogenesis cDNA array analysis Total RNA was isolated from different organs and 20 mg were resolved in 0.8% agaroseEE6% formaldehyde gel, followed by blotting onto a nylon membrane. The blots were hybridized with random primed human TIMP-1 cDNA probe for 1 h at 68 C, washed 10 times with 2Â SSC/0.05% SDS at room temperature and three times with 0.1Â SSC/0.1% SDS for 15 min each time at 50 C. CD31 mRNA expression was used, in parallel with CD-31 immunostaining of tumor blood vessels, to evaluate microvascular density in the mammary tumors. Total RNA was extracted from the tumors and RTEEPCR was carried out with 30 cycles at 94 C for 1 min, 58 C for 2 min and 72 C for 3 min, using the following CD-31 primers: GGAATTCCCCATTGAGGCGC (sense) and CCATGATGCTACTGGCTTTGG (antisense). Densitometric analysis was performed with a Lumi-Imager and b-actin served as an internal control. Angiogenesis-specific gene expression was analyzed in pooled RNA samples (5 mg) from four`High' TIMP-1 expressing MMTV-TIMP-1/MMTV-MT tumors and four MMTV-MT only tumors. GEAarray TM Q series mouse angiogenesis array (SuperArray, Bethesda, MD) was used and the samples analyzed according to the manufacturer's instructions.
ELISA, zymography and western blot analysis Frozen tissues and tumors were homogenized in a glass homogenizer with extraction buffer (50 mM TrisEEHCl pH 7.5, 1.0 mM EDTA, 1.0 mM PMSF, 10 mg/ml aprotinin and 10 mg/ml leupeptin), followed by centrifugation (10 000 g) at 4
C for 20 min twice. Protein concentration was determined, using MicroBCA protein assay reagents (Pierce, Rockford, IL). Transgenic TIMP-1 protein levels in the tissue and plasma samples were measured by human TIMP-1 ELISA (Amersham Pharmacia Biotech, NJ) according to the manufacturer's protocol. Gelatin zymography was performed to assess MMP-2 and MMP-9 activities in the mammary carcinomas. Tumor homogenates, containing 40 mg protein, were applied without heating or reduction to 10% zymogram (0.1% gelatin) or 4EE16% zymogram (0.1% casein) gel electrophoresis (Invitrogen, Carlsbad, CA) for assessment of MMP-2, MMP-9 and MMP-3 activities. After electrophoresis, the gels were washed for 30 min with 2.7% Triton X-100, then incubated in 50 mM TrisEEHCl containing 5 mM CaCl 2 , 200 mM NaCl and 0.2% Brij-35 for 30 min at room temperature and 16 h at 37 C. After incubation, the gels were stained with Colloidal Blue Staining Kit (NOVEX, San Diego, CA) and destained with water. Gelatinolytic and caseinolytic bands were visible as clear zones against a blue background. The active MMP-2 and MMP-9 levels in the mammary tumors were quantified by MMP-2 and MMP-9 activity assay kits according to the manufacture's instructions (Amersham Pharmacia Biotech, NJ) (n 4). The amount of active MMP-2 and MMP-9 was displayed as nanograms per gram of tumor protein.
Reverse zymography was performed to assess TIMP-1 activity in plasma samples and extracts of normal mammary glands, as well as tumor and plasma samples from mice with similar size tumors. In brief, 12% (w/v) SDSEEpolyacrylamide gels were prepared with 1 mg/ml gelatin and 160 ng/ml pro-MMP-9 (Oncogene, Boston, MA). Each sample was applied in non-reducing loading buffer. The gels were run at 120 V for 90 min, then washed twice with 2.5%(v/v) Triton X-100 in 50 mM TrisEEHCl (pH 7.5) and 5 mM CaCl 2 , 30 min each. The gels were then incubated in 50 mM TrisEEHCl pH 7.5 and 5 mM CaCl 2 for 14EE16 h at 37 C. After staining the gels in Colloidal Blue (Invitrogen, Carlsbad, CA) for 3 h, they were destained in deionized water. The MMP inhibitory TIMP-1 activity, which did not distinguish between human and endogenous mouse TIMP-1, was visualized as a dark blue band against the MMP-9 digested background. Western blot analysis of the angiogenic factors, VEGF, basic fibroblast growth factor (bFGF), and transforming growth factor beta (TGFb) was performed on tumor lysates (40 mg) of three individual tumors from each of the following three groups: Alb-TIMP-1/MMTV-MT, MMTV-TIMP-1/MMTV-MT and MMTV-MT only. Following gel electrophoresis and transfer to a PVDF membrane (Invitrogen, Carlsbad, CA), hybridization was carried out, using 1:500 dilution of VEGF, bFGF, and TGFb antibodies (all from Santa Cruz Biotechnology, Santa Cruz, CA). The proteins were visualized by using DAKO's HRP-conjugated secondary antibodies and Amersham's enhanced chemiluminescence detection system.
Histology and immunohistochemistry
H&E stained sections of all major organs from the Alb-TIMP-1, MMTV-TIMP-1 and wt mice were examined microscopically. Mammary gland whole mounts were prepared as described previously (54) . Cell proliferation was examined by PCNA staining of representative histological sections. In vivo cell proliferation was assessed in 13-week-old tumor bearing MMTV-TIMP-1 mice and their wt littermates. Two hours prior to death, the mice received BrdU intraperitoneally (75 mg/g body wt). Histological sections of formalin fixed tumors were stained, using a BrdU staining kit (Oncogene, Boston, MA) according to the company's instructions. Apoptotic cells in tumor sections were detected by using TumorTACS (Trevigen, Gaithersburg, MD). Microvascular density was quantified in frozen sections by immunostaining of CD-31, using anti-mouse CD31 monoclonal antibody (BD PharMingen, San Diego, CA) and the ABC method (Vector Laboratories, Burlingame, CA). Proliferative and apoptotic indices were determined by counting positive cells in 15 random microscopic fields at 400Â magnification. The microvascular density was assessed by counting CD-31 positive microvessels in 15 fields at 200Â magnification, choosing the areas with the highest vascular density. Student's t-test was used for statistical analyses of cell proliferation, apoptosis and microvascular density.
Results
Mouse models and biological activity of transgenic TIMP-1 The Alb enhancer/promoter was used to target the liver for production of large amounts of transgenic TIMP-1 and chronic release into the systemic circulation ( Figure 1A ). Of the five Alb-TIMP-1 founders produced, the founder with the highest hepatic hTIMP-1 expression was chosen for the development of a transgenic line. Northern blot analysis revealed that transgenic TIMP-1 expression was restricted to the liver ( Figure 1B) . The highest human TIMP-1 plasma levels,~800 ng/ml, were observed at 2 weeks of age. The levels then dropped sharply to~500 ng/ml at 4 weeks of age ( Figure 1C ), which reflects a decrease in the activity of the Alb promoter during the first 6 weeks after birth (51) . The TIMP-1 plasma levels were then maintained at 400EE500 ng/ml for the remainder of the 30-week experimental period.
Reverse zymography was used to assess total TIMP-1 MMP inhibitory activity in plasma samples. Consistent with the presence of transgenic TIMP-1, in addition to mouse TIMP-1, in the plasma, the Alb-TIMP-1 mice possessed 2EE3-fold higher circulating TIMP-1 activity than the wt littermates at 6 weeks of age ( Figure 1D ), suggesting that transgenic TIMP-1 contributed to the MMP-9 inhibitory activity. Suggestive of continuous release of transgenic TIMP-1 from the liver into the circulation, a positive relationship was found between the liver and plasma levels of TIMP-1 in a group of nine 6-week-old Alb-TIMP-1 mice ( Figure 1E ). No macro-or microscopic abnormalities were detected in major organs of the Alb-TIMP-1 mice (examined up to 6 months of age) (not shown). Furthermore, results of liver function tests in all age groups of the heterogenous Alb-TIMP-1 mice were within normal limits (data not shown).
For targeting of the mammary gland, human TIMP-1 cDNA was placed under the control of the MMTV-LTR (Figure 2A) . Consistent with the reported lack of organ specificity of the MMTV promoter in transgenic models (54) , TIMP-1 expression was observed in salivary glands, lungs and spleen, besides mammary glands in the MMTV-TIMP-1 mice ( Figure 2B ). An age-dependent increase in TIMP-1 levels was observed in mammary glands of heterozygous MMTV-TIMP-1 mice ( Figure 2C ). This is consistent with tissue re-organization, associated with ductal branching during mammary gland development. Similarly, a strong MMP-9 inhibitory zone at a molecular weight of~29 kDa, corresponding to TIMP-1, was observed in mammary glands of 6-week-old MMTV-TIMP-1 Tumor growth suppressed by circulating but not mammary TIMP-1 mice, whereas TIMP-1 activity was not detected in mammary glands of the wt littermates ( Figure 2D ). Microscopic examination of whole mount preparations of mammary glands from 6 to 20-week-old virgin MMTV-TIMP-1 female mice and the wt littermates showed no abnormalities in ductal branching or terminal end bud development (not shown). Similarly, no histological abnormalities were observed in H&E stained sections of mammary glands from pregnant and lactating MMTV-TIMP-1 mice (not shown). Normal size and excellent general health of the pups of heterozygous Alb-TIMP-1 and MMTV-TIMP-1 mice further established that mammary gland development and lactation was not affected by the transgenic TIMP-1.
Circulating but not mammary transgenic TIMP-1 suppresses tumor growth In order to determine the effect of circulating TIMP-1 on mammary carcinogenesis, the Alb-TIMP-1 and MMTV-TIMP-1 mice were either given DMBA orally or crossed with MMTV-MT-transgenic mice. In the initial DMBA mammary carcinogenesis study, the appearance of macroscopic tumors was recorded biweekly for a 30-week experimental period in heterozygous Alb-TIMP-1 mice and their wt littermates. During the 30-week study, macroscopic mammary carcinomas were detected in four of 16 (25%) of the Alb-TIMP-1 mice and 10 of 12 (83.3%) of the wt littermates (P 0.0032) ( Figure 3A) . Also, the total number of tumors was lower in the Alb-TIMP-1 mice (four tumors) than the wt mice (21 tumors). However, the time until macroscopic tumors were first detected (10 weeks after the last DMBA dose) was not different in the two groups. A separate 12-week study was undertaken to determine if TIMP-1 suppressed the early stages of DMBA-induced mammary carcinogenesis in the Alb-TIMP-1 mice. Microscopic examination of H&E stained sections of mammary gland whole mounts, prepared at 4, 8 and 12 weeks post-DMBA, showed no difference in the number, size or microscopic appearance of hyperplastic lesions and early carcinomas between the Alb-TIMP-1 and wt groups (not shown). The data suggest that TIMP-1 did not interfere with the initial stages of DMBA-induced mammary carcinogenesis. They also ruled out that impairment of metabolic activation of DMBA was responsible for the decreased tumor incidence.
Alb-TIMP-1 mice were crossed with MMTV-MT transgenic mice to generate metastatic mammary carcinomas. At the end of the 18-week experimental period, tumor incidence was 100% in both Alb-TIMP-1/MMTV-MT mice and the MMTV-MT only littermates. Similarly, there was insignificant difference in the average tumor multiplicity (eight and nine per mouse) between the two groups. However, the median value of the combined tumor weight per mouse was significantly lower in the Alb-TIMP-1/MMTV-MT mice (5.68 AE 0.79 g) than the MMTV-MT only mice (9.72 AE 1.09 g; P 5 0.01) ( Figure 3B) . Also, the median weight per tumor was significantly lower in the Alb-TIMP-1/MMTV-MT (0.71 AE 0.12 g) than the MMTV-MT only mice (1.06 AE 0.12 g; P 5 0.01). Microand macroscopic lung metastases were detected in 17 of the 23 Alb-TIMP-1/MMTV-MT mice (73.9%) and 22 of the 23 MMTV-MT only mice (95.7%; P 0.042) (Table I) . However, the mean number and the average area of lung metastases per mouse and the mean area of individual metastasis were not statistically different in the two groups (Table I) .
DMBA and MT-induced mammary carcinogenesis studies were also carried out in the MMTV-TIMP-1 mice. The DMBA study, which was terminated 10 weeks after the last DMBA dose, showed insignificant difference in the combined tumor weight (P 0.92) between the MMTV-TIMP-1 mice and wt littermates ( Figure 3C ). Also, an 18-week MT-induced mammary carcinogenesis study showed no difference in the combined tumor weight between the MMTV-TIMP-1/ MMTV-MT and the MMTV-MT only littermates ( Figure 3D) . Furthermore, the incidence of lung metastases, the average number and the average area of metastases were not significantly different in the two groups (Table I) .
The histopathology of the mammary carcinomas induced by DMBA and MT was that of adenocarcinoma with papillary and tubular growth patterns except for a few DMBA-induced carcinomas in the Alb-TIMP-1 mice, which displayed squamous differentiation (not shown). TIMP-1 had no impact on the growth patterns of the carcinomas, the amount of tumor stroma, or the extent of type IV collagen and laminin immunopositivity in the tumor stroma (not shown).
Transgenic TIMP-1 levels were compared in size-matched tumors of the Alb-TIMP-1/MMTV-MT and MMTV-TIMP-1/ MT only mice. The levels were variable within each group and a big difference was observed between the groups ( Figure 4A and B) . The highest TIMP-1 level in the Alb-TIMP-1/MMTV-MT group was~6.4 ng/mg ( Figure 4A ). In the MMTV-TIMP-1/MMTV-MT group, the mammary Tumor growth suppressed by circulating but not mammary TIMP-1 tumors were divided into`high' and`low' subgroups ( Figure 4B ). The highest TIMP-1 level in the`low' subgroup of 13 tumors was~35 ng/mg and the highest level in the`high' subgroup of six tumors was close to 10 000 ng/mg. At the end of the experimental period, the average transgenic TIMP-1 plasma level in the tumor bearing MMTV-TIMP-1/MMTV-MT group was considerably higher than the average TIMP-1 level in the ALB-TIMP-1/MMTV-MT group ( Figure 4C 3 and 4) . Similarly, TIMP-1 activity was barely detected in the plasma from the tumor bearing MMTV-MT only mice (lanes 5 and 6), compared with strong TIMP-1 activity in the plasma from the MMTV-TIMP-1/MMTV-MT mice (lanes 7 and 8) .
The possibility was examined that over-expression of TIMP-1 could affect MMP expression and activities in the MT-induced mammary carcinomas. RTEEPCR analysis showed no difference in MMP-2 and MMP-9 mRNA levels in tumors from the transgenic and MMTV-MT only littermates (not shown). Zymographic studies of lysates from individual tumors showed variable gelatinolytic MMP-2 and MMP-9 activities and no clear difference between the TIMP-1 transgenic and MMTV-MT only groups (not shown). However, quantitative analysis of active MMP-2 and MMP-9 in individual sizematched tumors showed that the Alb-TIMP-1/MMTV-MT group displayed lower levels of active MMP-2 (P 5 0.05) Comparison of incidence, number and area of lung metastases between MMTV-MT (23) and Alb-TIMP-1/MMTV-MT (n 23) mice or MMTV-MT (n 12) and MMTV-TIMP-1/MMTV-MT (n 12) mice. Shown are the number and percentage (%) of mice with metastases, the average number of metastases AE SD and the average area (mm 2 ) of metastases AE SD. P value was calculated with MannEEWhitney U-test. Figure 5 ). In the Alb-TIMP/MT tumors, TIMP-1 positivity was mostly deposited in the tumor stroma ( Figure 5A ). In contrast, TIMP-1 was more diffusely distributed in the MMTV-TIMP-1/MT tumors, which is consistent with the release of transgenic TIMP-1 by individual carcinoma cells into the surrounding environment ( Figure 5B ). TIMP-1 immunopositivity was not detected in MMTV-MT only tumors ( Figure 5C and D) .
Circulating and mammary TIMP-1 have opposite effects on tumor cell proliferation Immunohistochemical analysis of size-matched Alb-TIMP-1/ MMTV-MT and MMTV-MT only tumors was carried out to measure proliferative and apoptotic activities, as well as microvascular density. The average number of proliferating tumor cells, judged by PCNA positivity, was significantly lower in the Alb-TIMP-1/MMTV-MT mice than in the MMTV-MT only mice (P 5 0.01) ( Figure 6A ). There was also a significant decrease in the average number of apoptotic tumor cells in the Alb-TIMP-1/MMTV-MT mice (P 5 0.001) ( Figure 6B) . Surprisingly, insignificant difference in microvascular density was observed between the Alb-TIMP-1/ MMTV-MT and MMTV-MT only tumors ( Figure 6C ) and semi-quantitative RTEEPCR analysis of CD31 mRNA levels showed no difference between the two groups (not shown). More data on angiogenesis associated factors are described in the next paragraph on MMTV-TIMP-1 tumors.
The`high' TIMP-1 expressing MMTV-MT-/MMTV-MT tumor group, but not the`low' expressing group, showed a significant increase in the number of PCNA positive cells, compared with the MMTV-MT only group (P 5 0.05) ( Figure 7A ). An association between the transgenic TIMP-1 levels and the proliferative activity was further established when the TIMP-1 levels were plotted against the number of PCNA positive cells in the tumors ( Figure 7B ). In contrast to the Alb-TIMP-1/MMTV-MT tumors, the`high' TIMP-1 expressing tumors did not differ significantly from the MMTV-MT only tumors in the number of apoptotic cells Discussion TIMP-mediated suppression of tumor invasion and metastases in experimental models has been attributed to their capacity to inhibit MMPs, which can collectively degrade all structural components of the ECM and are up-regulated in malignant tumors (55EE57). Conversely, TIMP-1 is over-expressed in various types of human malignancies (32EE46) and over-expression of TIMP-1 in breast carcinoma cells results in increased tumorigenesis (30) . Discoveries of TIMP-1 as a growth factor (8EE11), an inhibitor of angiogenesis (13) and a survival factor (18) have further complicated attempts to elucidate its role in carcinogenesis.
TIMP-1 is widely distributed in the body and is present in the circulation, body fluids and interstitial tissues (4, 58) . The reported median value of TIMP-1 plasma levels in healthy volunteers ranged widely from~70 to 610 ng/ml (59EE61). Because ELISA for mouse TIMP-1 was not available, we were unable to measure the endogenous TIMP-1 plasma levels in the transgenic mice. Instead, semi-quantitative reverse zymography was used to assess total TIMP-1 activity, which was estimated to be 2EE3-fold higher in the plasma of the Alb-TIMP-1 mice than wt littermates at 6 weeks of age. In view of the data showing that transgenic TIMP-1 plasma levels of 400EE500 ng/ml can be maintained for at least 30 weeks without adverse effects on the animals, this transgenic model is well suited for long-term studies to assess the systemic effects of biologically active TIMP-1 on various disease processes that involve excessive MMP-mediated tissue degradation, including cancer. Chronic exposure to elevated levels of circulating transgenic TIMP-1 resulted in decreased tumor weights and lower incidence of lung metastases in the Alb-TIMP-1 mice. MMP inhibition is the TIMP-1 function that is generally implemented in tumor growth suppression (62) . This is supported by our data showing significantly decreased levels of active MMP-2 and MMP-9 in the tumors of the Alb-TIMP-1/MMTV-MT mice. MMPs promote the early stages of tumor development through proteolytic degradation of the ECM, which can alter the mechanism controlling cell proliferation and promote neoplastic transformation (63, 64) . Elevated MMP-2 transcripts have been reported in stromal cells surrounding ductal and lobular carcinomas in situ and additionally, elevated MMP-1 transcripts were observed in invasive breast carcinomas (65) .
Stromal reaction is allegedly critical for the progression of hyperplastic foci to carcinomas in DMBA-induced mammary carcinomas in rats (66) . Although TIMP-1 did not affect the number of early lesions in the DMBA treated Alb-TIMP-1 mice, the data on decreased tumor incidence suggest that TIMP-1 prevented hyperplastic lesions from progressing to carcinomas and/or halted the growth of microscopic carcinomas. TIMP-1 may also decrease the bioavailability of growth factors, which are released from the ECM through MMP-mediated degradation (67) . Extrapolating from our transgenic data to human breast cancer, it is conceivable that chronic delivery of TIMP-1 through the circulation can halt the progression of in situ and the early stages of breast cancer.
The MT antigen is a powerful oncogene, which alone can transform cells. When placed under the control of the MMTV-LTR, it induces spontaneous mammary carcinomas, which are of ductal origin (68) . The main advantage of using the MMTV-MT model is that the mammary carcinomas arise synchronously and are metastatic (68) . In considering the power of the MT oncogene to drive tumorigenesis, it was remarkable that a moderate increase in circulating TIMP-1 levels could significantly suppress tumor growth and the incidence of metastases in the Alb-TIMP-1/MMTV-MT mice. We attribute this to the availability of the blood-derived transgenic TIMP-1 in the tumor environment from the onset of mammary carcinogenesis. It was surprising however, that vascular density was not decreased in the MT-induced tumors of either the Alb-TIMP-1 or the MMTV-TIMP-1 mice. It is well established that TIMP-1 acts as an inhibitor in angiogenesis, both in angiogenesis assays (12EE14) and in experimental tumor models (69) .
Decreased neovascularization was also demonstrated in tumor allografts in the Alb-TIMP-1 model (27,70). We do not have an explanation for the inability of TIMP-1 to suppress neovascularization in the present study. Decreased expression of common angiogenic factors l like VEGF, bFGF and TGFb was ruled out in both the Alb-TIMP-1 and MMTV-TIMP-1 models. Moreover, cDNA array analysis of 96 angiogenesisassociated genes revealed an insignificant difference in gene expression between pooled RNA samples from the`high' TIMP-1 expressing and the MMTV-MT only tumors. One may speculate that TIMP-1 was incapable of counteracting the powerful angiogenic forces of the MT mammary carcinogenesis model. TIMP-1 acts as an anti-apoptotic factor in human breast epithelial cells (20, 21) . We found evidence to that effect in the tumor cells of the Alb-TIMP-1/MMTV-MT mammary carcinomas. A decrease in both proliferative and apoptotic activities in those tumors recapitulates the paradoxical functions of TIMP-1 (58, 71) . Nevertheless, the reduced tumor weights suggested that the capability of TIMP-1 to inhibit tumor cell proliferation was stronger than its anti-apoptotic/ survival effects.
The growth suppressive effects of TIMP-1 in the Alb-TIMP-1 mice were not recapitulated in the MMTV-TIMP-1 mice. This was surprising when considering the large amount of transgenic TIMP-1 released from the tumors of the`high' expressing carcinomas into the circulation. The ineffectiveness of the circulating TIMP-1 in suppressing tumor growth in the MMTV-TIMP-1/MMTV-MT mice may be due to the fact that high circulating TIMP-1 levels were not present at the onset of tumorigenesis. Also, the association between high TIMP-1 levels and increased proliferative activity in these tumors suggests that high intracellular TIMP-1 has growth promoting effects. This is in keeping with the reported growth promoting function of TIMP-1, which involves activation of Ras and the mitogen-activated protein kinase (MAPK) pathway (8, 72) . TIMP-1 is also implemented in growth promotion of human urothelial cancer where the Ki-67 labeling index was found to correlate with the TIMP-mRNA levels (73) .
The lack of tumor weight gain of the`High' TIMP-1 expressing tumors with increased proliferative activity has not been resolved so far and requires further studies. The outcome of the mammary carcinogenesis studies in transgenic Alb-TIMP-1 and MMP-TIMP-1 models stresses the complex biological effects of TIMP-1 on the tumor environment. It may also reflect paradoxical functions of intra-and extracellular TIMP-1. This is in accord with findings by Goss et al. in Min mice, which develop spontaneous intestinal tumors (74) . Systemic treatment of the Min mice with synthetic MMP inhibitors suppressed intestinal tumor growth, whereas overexpression of TIMP-1 in the gastrointestinal tract had either no effect or increased Min tumor multiplicity.
An imbalance in favor of MMPs is thought to be critical in promoting tumor dissemination. Although not highly significant, there was decreased incidence of lung metasases in the Alb-TIMP-1/MMTV-MT mice. This finding concurs with inhibition of intravenous metastases, following intraperitoneal administration of recombinant TIMP-1 (24) . It is intriguing that the incidence of lung metastases was not decreased in the MMTV-TIMP-1/MMTV-MT mice, which displayed higher terminal TIMP-1 plasma levels than the Alb-TIMP-1/ MMTV-MT mice.
In summary, the data from our transgenic models indicate that the presence of elevated TIMP-1 plasma levels from the onset of tumorigenesis is effective in suppressing mammary tumor growth and metastases. This suggests that chronic systemic TIMP-1 treatment will be beneficial in the treatment of various human diseases that involve tissue destruction from excessive MMP activities. Although synthetic MMP inhibitors have been efficient in halting tumor growth and dissemination in rodent models, they have yielded negative or borderline results in clinical trials of late stage malignancies (71, 75) . Further studies are required to get deeper insight into the biology of the MMPs that are crucial for the advancement of the early stages of human breast cancer. Data from such studies will be useful for the design of specific synthetic MMP inhibitors that have fewer side effects and are more effective than the broad-spectrum MMP inhibitors used in clinical trials previously. It will be very interesting to see whether such molecules will be of therapeutic benefit in adjuvant treatment of cancer and/or as chemopreventive agents.
